Articles published by Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Tickers LBPH
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.